HIV monoclonal antibodies
| dc.contributor.author | Fowler, G. Mary | |
| dc.date.accessioned | 2022-02-14T09:35:46Z | |
| dc.date.available | 2022-02-14T09:35:46Z | |
| dc.date.issued | 2014 | |
| dc.description.abstract | While formula feeding is recommended for HIV-infected mothers in industrialized countries, breastfeeding is the cornerstone of infant survival in many low-resource countries. In such settings, the World Health Organization (WHO) recommends that HIV-infected mothers should breastfeed for 12 months with concurrent infant or maternal ARV prophylaxis to reduce transmission risk [2]. However, new reports suggest that weaning prior to age 18 months is associated with elevated morbidity and mortality among HIV-exposed, uninfected children even in clinical trial settings [4]. Additionally, the use of ARV prophylaxis by mother or infant during breastfeeding can reduce but does not eliminate transmission risk and relies on strict adherence to daily drug administration. Breakthrough infections at rates as high as 2–5% by age six months and 6% by age 12 months have been observed in breastfeeding infants of HIV-infected mothers who have been provided with triple ARV drug therapy during pregnancy and breastfeeding [4],[6]. | en_US |
| dc.identifier.uri | https://doi.org/10.1371/journal.pmed.1001616 | |
| dc.identifier.uri | https://nru.uncst.go.ug/xmlui/handle/123456789/2105 | |
| dc.language.iso | en | en_US |
| dc.publisher | PLoS Med | en_US |
| dc.subject | HIV | en_US |
| dc.subject | HIV Monoclonal antibodies | en_US |
| dc.subject | Mother-to-child HIV transmission | en_US |
| dc.title | HIV monoclonal antibodies | en_US |
| dc.title.alternative | : a new opportunity to further reduce mother-to-child HIV transmission | en_US |
| dc.type | Article | en_US |